文献速递心境障碍

鼻内艾司氯胺酮快速改善自杀高危抑郁患者症状的随机对照研究

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
PubMed 文献 · Am J Psychiatry · 2018-04-16

该双盲、多中心、概念验证研究将68名自杀风险迫近的重性抑郁患者随机分配至鼻内艾司氯胺酮84mg或安慰剂组,每周两次共4周,均联合综合标准治疗。结果显示艾司氯胺酮组在首次给药后4小时和约24小时的MADRS评分改善显著优于安慰剂组,但第25天无显著差异;MADRS自杀思维条目仅在4小时显著改善,临床总体自杀风险判断各时点均无统计学差异。

要点

  • 鼻内艾司氯胺酮84mg联合标准治疗在4小时和24小时显著改善抑郁症状。
  • MADRS自杀思维条目仅在4小时显著改善,24小时和第25天无显著差异。
  • 临床总体自杀风险判断在各时点均无统计学显著差异。

核心结论

  • 鼻内艾司氯胺酮联合综合标准治疗可能快速改善自杀风险迫近抑郁患者的抑郁症状,包括部分自杀意念指标。

研究设计与样本

  • 双盲、多中心、概念验证研究,68名自杀风险迫近的重性抑郁患者随机接受鼻内艾司氯胺酮84mg或安慰剂,每周两次共4周,均联合综合标准治疗。

主要发现

  • MADRS评分在4小时(最小二乘均值差=-5.3,SE=2.10;效应量=0.61)和约24小时(最小二乘均值差=-7.2,SE=2.85;效应量=0.65)艾司氯胺酮组显著优于安慰剂组,第25天无显著差异(最小二乘均值差=-4.5,SE=3.14;效应量=0.35)。
  • MADRS自杀思维条目评分在4小时艾司氯胺酮组显著改善(效应量=0.67),24小时(效应量=0.35)和第25天(效应量=0.29)无显著差异。
  • 临床总体自杀风险判断评分组间降低在各时点均无统计学差异。
  • 艾司氯胺酮组最常见不良事件为恶心、头晕、分离、异味和头痛。

关键数值与推荐

  • 鼻内艾司氯胺酮剂量为84mg,每周两次,共4周,联合综合标准治疗。
  • 主要疗效终点为MADRS评分从基线至首次给药后4小时的变化。

临床怎么用

  • 对于自杀风险迫近的重性抑郁患者,可考虑鼻内艾司氯胺酮84mg联合综合标准治疗以快速改善抑郁症状。
  • 需关注给药后4小时内自杀意念的改善,但临床总体自杀风险判断未见显著差异,应持续评估。

局限性

  • 样本量较小(68例),为期4周,属概念验证研究,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors compared the efficacy of standard-of-care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among individuals at imminent suicide risk. METHOD: In a double-blind, multicenter, proof-of-concept study, 68 participants were randomly assigned to receive esketamine (84 mg) or placebo twice weekly for 4 weeks, in addition to comprehensive standard-of-care treatment. The primary efficacy endpoint was change in score from baseline to 4 hours after initial dose on the Montgomery-Åsberg Depression Rating Scale (MADRS). Clinician global judgment of suicide risk (from the Suicide Ideation and Behavior Assessment Tool) was also assessed. Secondary endpoints included these measures at 24 hours and double-blind endpoint at day 25. RESULTS: A significantly greater improvement in MADRS score was observed in the esketamine group compared with the placebo group at 4 hours (least-square mean difference=-5.3, SE=2.10; effect size=0.61) and at ∼24 hours (least-square mean difference=-7.2, SE=2.85; effect size=0.65), but not at day 25 (least-square mean difference=-4.5, SE=3.14; effect size=0.35). Significantly greater improvement was also observed in the esketamine group on the MADRS suicidal thoughts item score at 4 hours (effect size=0.67), but not at 24 hours (effect size=0.35) or at day 25 (effect size=0.29). Between-group reductions in clinician global judgment of suicide risk scores were not statistically different at any time point. The most common adverse events among participants in the esketamine group were nausea, dizziness, dissociation, unpleasant taste, and headache. CONCLUSIONS: These preliminary findings indicate that intranasal esketamine compared with placebo, given in addition to comprehensive standard-of-care treatment, may result in significantly rapid improvement in depressive symptoms, including some measures of suicidal ideation, among depressed patients at imminent risk for suicide.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018. PMID: 29656663. doi:10.1176/appi.ajp.2018.17060720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。